Safety and Efficacy of a Novel Malathion Formulation in the Treatment of Head Lice

Lice Infestations Clinical Trial

Official title: A Multi-Center Phase III Study to Evaluate MALG, a Novel Malathion 0.05%Formulation, for the Control of Head Lice in Pediatric and Adult Subjects With Pediculosis Capitis

Status Completed

Clinical Trial Summary

Current treatments for head lice include over-the-counter products such as permethrin and prescription products such as OVIDE (malathion 0.5%) lotion. In a previous phase II study, a novel, easy-to-use malathion 0.5% formulation was found to be a safe treatment for head lice. The current study will compare the efficacy and safety of this novel formulation of malathion with OVIDE and with an over-the-counter permethrin product.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lice Infestations

• NCT number: NCT00244439
• Study type: Interventional
• Source: Taro Pharmaceuticals USA
• Status: Completed
• Phase: Phase 3
• Start date: December 2005
• Completion date: December 2006